Cargando…

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?

Detalles Bibliográficos
Autores principales:	Sgalla, Giacomo, Richeldi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462699/ https://www.ncbi.nlm.nih.gov/pubmed/32402013 http://dx.doi.org/10.36416/1806-3756/e20200193

Ejemplares similares

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
por: Cerri, Stefania, et al.
Publicado: (2016)

Idiopathic pulmonary fibrosis: pathogenesis and management
por: Sgalla, Giacomo, et al.
Publicado: (2018)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Out of our comfort zone
por: Thomson, A., et al.
Publicado: (2020)

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
por: Cottin, Vincent, et al.
Publicado: (2014)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

Ironing Out the Roles of Macrophages in Idiopathic Pulmonary Fibrosis
por: O’Dwyer, David N., et al.
Publicado: (2019)

Reply to Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj
por: Sgalla, Giacomo, et al.
Publicado: (2022)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
por: Di Bidino, Rossella, et al.
Publicado: (2022)

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory
por: Raghu, Ganesh, et al.
Publicado: (2019)

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
por: Jones, Mark G., et al.
Publicado: (2016)

Neonatal seizures: stepping outside the comfort zone
por: Hashish, Menna, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Step Forward
por: Vancheri, Carlo, et al.
Publicado: (2022)

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
por: Rochwerg, Bram, et al.
Publicado: (2016)

‘I Can Step outside My Comfort Zone.’
por: McFadyen, Morag C. E., et al.
Publicado: (2017)

Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go Global?
por: Funke-Chambour, Manuela
Publicado: (2020)

Career courage: discover your passion, step out of your comfort zone, and create the success you want
por: Kelley, Katie C
Publicado: (2016)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment
por: Morais, António
Publicado: (2019)

The human thermoneutral and thermal comfort zones: Thermal comfort in your own skin blood flow
por: Schlader, Zachary J
Publicado: (2014)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
por: Millan-Billi, Paloma, et al.
Publicado: (2018)

State of the Art in Idiopathic Pulmonary Fibrosis
por: El Agha, Elie, et al.
Publicado: (2022)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

The road to self-leadership development: busting out of your comfort zone
por: Ross, Stanley C
Publicado: (2015)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

Autophagy in Idiopathic Pulmonary Fibrosis: Predisposition of the Aging Lung to Fibrosis?
por: Zmijewski, Jaroslaw W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h20nltoc84saoagromg2fvbcgk